Epithelial-to-Mesenchymal Transition: Epigenetic Reprogramming Driving Cellular Plasticity

Trends in Genetics

Volumn 33, Issue 12, 2017, Pages 943-959

  Skrypek, Nicolas ^a,b   Goossens, Steven ^a,b,c   De Smedt, Eva ^a,b   Vandamme, Niels ^a,b,d   Berx, Geert ^a,b  

^a GHENT UNIVERSITY   (Belgium)

^b CANCER RESEARCH INSTITUTE GHENT CRIG   (Belgium)

^c GHENT UNIVERSITY HOSPITAL   (Belgium)

^d DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BMI1 PROTEIN; HISTONE DEACETYLASE; LONG UNTRANSLATED RNA; MICRORNA; MULTIPROTEIN COMPLEX; NURD COMPLEX; POLYCOMB REPRESSIVE COMPLEX 2; SWITCH SUCROSE NONFERMENTABLE COMPLEX; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR SIN3A; UNCLASSIFIED DRUG;

CANCER GENE THERAPY; CELL PLASTICITY; CHROMATIN ASSEMBLY AND DISASSEMBLY; DNA METHYLATION; EPIGENETICS; EPITHELIAL MESENCHYMAL TRANSITION; GENETIC REGULATION; HISTONE MODIFICATION; HUMAN; NUCLEAR REPROGRAMMING; PRIORITY JOURNAL; REVIEW; CELL DIFFERENTIATION; GENETIC EPIGENESIS; GENETICS;

CELL DIFFERENTIATION; CELL PLASTICITY; CELLULAR REPROGRAMMING; EPIGENESIS, GENETIC; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; TRANSCRIPTION FACTORS;

EID: 85029452284     PISSN: 01689525     EISSN: 13624555     Source Type: Journal    
DOI: 10.1016/j.tig.2017.08.004     Document Type: Review

References (173)

1. Greenburg, G., Hay, E.D., Epithelia suspended in collagen gels can lose polarity and express characteristics of migrating mesenchymal cells. J. Cell Biol. 95 (1982), 333–339.
2. Thiery, J.P., et al. Epithelial-mesenchymal transitions in development and disease. Cell 139 (2009), 871–890.
3. Li, R., et al. A mesenchymal-to-epithelial transition initiates and is required for the nuclear reprogramming of mouse fibroblasts. Cell Stem Cell 7 (2010), 51–63.
4. Samavarchi-Tehrani, P., et al. Functional genomics reveals a BMP-driven mesenchymal-to-epithelial transition in the initiation of somatic cell reprogramming. Cell Stem Cell 7 (2010), 64–77.
5. Guo, W., et al. Slug and Sox9 cooperatively determine the mammary stem cell state. Cell 148 (2012), 1015–1028.
6. Tam, W.L., Weinberg, R.A., The epigenetics of epithelial-mesenchymal plasticity in cancer. Nat. Med. 19 (2013), 1438–1449.
7. Nieto, M.A., et al. EMT: 2016. Cell 166 (2016), 21–45.
8. Grande, M.T., et al. Snail1-induced partial epithelial-to-mesenchymal transition drives renal fibrosis in mice and can be targeted to reverse established disease. Nat. Med. 21 (2015), 989–997.
9. Thiery, J.P., Sleeman, J.P., Complex networks orchestrate epithelial-mesenchymal transitions. Nat. Rev. Mol. Cell Biol. 7 (2006), 131–142.
10. Chang, R., et al. Post-translational modifications of EMT transcriptional factors in cancer metastasis. Open Life Sci. 11 (2016), 237–243.
11. De Craene, B., Berx, G., Regulatory networks defining EMT during cancer initiation and progression. Nat. Rev. Cancer 13 (2013), 97–110.
12. van Roy, F., Berx, G., The cell-cell adhesion molecule E-cadherin. Cell. Mol. Life Sci. 65 (2008), 3756–3788.
13. Batlle, E., et al. The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nat. Cell Biol. 2 (2000), 84–89.
14. Comijn, J., et al. The two-handed E box binding zinc finger protein SIP1 downregulates E-cadherin and induces invasion. Mol. Cell 7 (2001), 1267–1278.
15. Hajra, K.M., et al. The SLUG zinc-finger protein represses E-cadherin in breast cancer. Cancer Res. 62 (2002), 1613–1618.
16. Vesuna, F., et al. Twist is a transcriptional repressor of E-cadherin gene expression in breast cancer. Biochem. Biophys. Res. Commun. 367 (2008), 235–241.
17. Cano, A., et al. The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat. Cell Biol. 2 (2000), 76–83.
18. Eger, A., et al. DeltaEF1 is a transcriptional repressor of E-cadherin and regulates epithelial plasticity in breast cancer cells. Oncogene 24 (2005), 2375–2385.
19. Vandewalle, C., et al. SIP1/ZEB2 induces EMT by repressing genes of different epithelial cell-cell junctions. Nucleic Acids Res. 33 (2005), 6566–6578.
20. Peinado, H., et al. Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype?. Nat. Rev. Cancer 7 (2007), 415–428.
21. Lamouille, S., et al. Molecular mechanisms of epithelial-mesenchymal transition. Nat. Rev. Mol. Cell Biol. 15 (2014), 178–196.
22. Lehmann, W., et al. ZEB1 turns into a transcriptional activator by interacting with YAP1 in aggressive cancer types. Nat. Commun., 7, 2016, 10498.
23. Ponticos, M., et al. Regulation of collagen type I in vascular smooth muscle cells by competition between Nkx2.5 and delta EF1/ZEB1. Mol. Cell. Biol. 24 (2004), 6151–6161.
24. Gregoire, J.M., Romeo, P.H., T-cell expression of the human GATA-3 gene is regulated by a non-lineage-specific silencer. J. Biol. Chem. 274 (1999), 6567–6578.
25. Postigo, A.A., et al. Regulation of Smad signaling through a differential recruitment of coactivators and corepressors by ZEB proteins. EMBO J. 22 (2003), 2453–2462.
26. Postigo, A.A., Dean, D.C., Independent repressor domains in ZEB regulate muscle and T-cell differentiation. Mol. Cell. Biol. 19 (1999), 7961–7971.
27. Brabletz, S., Brabletz, T., The ZEB/miR-200 feedback loop – a motor of cellular plasticity in development and cancer?. EMBO Rep. 11 (2010), 670–677.
28. Brabletz, T., MiR-34 and SNAIL: another double-negative feedback loop controlling cellular plasticity/EMT governed by p53. Cell Cycle 11 (2012), 215–216.
29. Liu, F., et al. Beyond transcription factors: how oncogenic signalling reshapes the epigenetic landscape. Nat. Rev. Cancer 16 (2016), 359–372.
30. Arzate-Mejia, R.G., et al. Signaling epigenetics: novel insights on cell signaling and epigenetic regulation. IUBMB Life 63 (2011), 881–895.
31. Bird, A., DNA methylation patterns and epigenetic memory. Genes Dev. 16 (2002), 6–21.
32. Bhutani, N., et al. DNA demethylation dynamics. Cell 146 (2011), 866–872.
33. Lim, S.O., et al. Epigenetic changes induced by reactive oxygen species in hepatocellular carcinoma: methylation of the E-cadherin promoter. Gastroenterology 135 (2008), 2128–2140 2140. e1–e8.
34. Espada, J., et al. Regulation of SNAIL1 and E-cadherin function by DNMT1 in a DNA methylation-independent context. Nucleic Acids Res. 39 (2011), 9194–9205.
35. Fukagawa, A., et al. deltaEF1 associates with DNMT1 and maintains DNA methylation of the E-cadherin promoter in breast cancer cells. Cancer Med. 4 (2015), 125–135.
36. Stryjewska, A., et al. Zeb2 regulates cell fate at the exit from epiblast state in mouse embryonic stem cells. Stem Cells 35 (2016), 611–625.
37. Galvan, J.A., et al. TWIST1 and TWIST2 promoter methylation and protein expression in tumor stroma influence the epithelial-mesenchymal transition-like tumor budding phenotype in colorectal cancer. Oncotarget 6 (2015), 874–885.
38. Acun, T., et al. SIP1 is downregulated in hepatocellular carcinoma by promoter hypermethylation. BMC Cancer, 11, 2011, 223.
39. Li, A., et al. Pancreatic cancers epigenetically silence SIP1 and hypomethylate and overexpress miR-200a/200b in association with elevated circulating miR-200a and miR-200b levels. Cancer Res. 70 (2010), 5226–5237.
40. Chen, Y., et al. DNA methylation is associated with transcription of Snail and Slug genes. Biochem. Biophys. Res. Commun. 430 (2013), 1083–1090.
41. Neves, R., et al. Role of DNA methylation in miR-200c/141 cluster silencing in invasive breast cancer cells. BMC Res. Notes, 3, 2010, 219.
42. Li, H., et al. The EMT regulator ZEB2 is a novel dependency of human and murine acute myeloid leukemia. Blood 129 (2017), 497–508.
43. Lim, Y.Y., et al. Epigenetic modulation of the miR-200 family is associated with transition to a breast cancer stem-cell-like state. J. Cell Sci. 126 (2013), 2256–2266.
44. Bannister, A.J., Kouzarides, T., Regulation of chromatin by histone modifications. Cell Res. 21 (2011), 381–395.
45. McDonald, O.G., et al. Genome-scale epigenetic reprogramming during epithelial-to-mesenchymal transition. Nat. Struct. Mol. Biol. 18 (2011), 867–874.
46. Amente, S., et al. The histone LSD1 demethylase in stemness and cancer transcription programs. Biochim. Biophys. Acta 1829 (2013), 981–986.
47. Lin, Y., et al. The SNAG domain of Snail1 functions as a molecular hook for recruiting lysine-specific demethylase 1. EMBO J. 29 (2010), 1803–1816.
48. Feng, J., et al. Phosphorylation of LSD1 at Ser112 is crucial for its function in induction of EMT and metastasis in breast cancer. Breast Cancer Res. Treat. 159 (2016), 443–456.
49. Li, Y., et al. LSD1-mediated epigenetic modification contributes to ovarian cancer cell migration and invasion. Oncol. Rep. 35 (2016), 3586–3592.
50. Jie, D., et al. Positive expression of LSD1 and negative expression of E-cadherin correlate with metastasis and poor prognosis of colon cancer. Dig. Dis. Sci. 58 (2013), 1581–1589.
51. Ferrari-Amorotti, G., et al. Inhibiting interactions of lysine demethylase LSD1 with snail/slug blocks cancer cell invasion. Cancer Res. 73 (2013), 235–245.
52. Wang, J., et al. Opposing LSD1 complexes function in developmental gene activation and repression programmes. Nature, 446, 2007 882–827.
53. Goossens, S., et al. Oncogenic ZEB2 activation drives sensitivity toward KDM1A inhibition in T-cell acute lymphoblastic leukemia. Blood 129 (2017), 981–990.
54. Verstappen, G., et al. Atypical Mowat-Wilson patient confirms the importance of the novel association between ZFHX1B/SIP1 and NuRD corepressor complex. Hum. Mol. Genet. 17 (2008), 1175–1183.
55. Fu, J., et al. The TWIST/Mi2/NuRD protein complex and its essential role in cancer metastasis. Cell Res. 21 (2011), 275–289.
56. Wu, L.M., et al. Zeb2 recruits HDAC-NuRD to inhibit Notch and controls Schwann cell differentiation and remyelination. Nat. Neurosci. 19 (2016), 1060–1072.
57. Si, W., et al. Dysfunction of the reciprocal feedback loop between GATA3- and ZEB2-nucleated repression programs contributes to breast cancer metastasis. Cancer Cell 27 (2015), 822–836.
58. Peinado, H., et al. Snail mediates E-cadherin repression by the recruitment of the Sin3A/histone deacetylase 1 (HDAC1)/HDAC2 complex. Mol. Cell. Biol. 24 (2004), 306–319.
59. Javaid, S., et al. Dynamic chromatin modification sustains epithelial-mesenchymal transition following inducible expression of Snail-1. Cell Rep. 5 (2013), 1679–1689.
60. Xiao, W., et al. Trichostatin A, a histone deacetylase inhibitor, suppresses proliferation and epithelial-mesenchymal transition in retinal pigment epithelium cells. J. Cell. Mol. Med. 18 (2014), 646–655.
61. Sanchez-Tillo, E., et al. ZEB1 represses E-cadherin and induces an EMT by recruiting the SWI/SNF chromatin-remodeling protein BRG1. Oncogene 29 (2010), 3490–3500.
62. Jordan, N.V., et al. SWI/SNF chromatin-remodeling factor Smarcd3/Baf60c controls epithelial-mesenchymal transition by inducing Wnt5a signaling. Mol. Cell. Biol. 33 (2013), 3011–3025.
63. Liu, Y., et al. Downregulation of Bmi-1 suppresses epithelial mesenchymal transition in melanoma. Oncol. Rep. 37 (2017), 139–146.
64. Zhang, Z., et al. Bmi-1 promotes the invasion and migration of colon cancer stem cells through the downregulation of E-cadherin. Int. J. Mol. Med. 38 (2016), 1199–1207.
65. Paranjape, A.N., et al. Bmi1 regulates self-renewal and epithelial to mesenchymal transition in breast cancer cells through Nanog. BMC Cancer, 14, 2014, 785.
66. Liu, K., et al. Hypoxia promotes vasculogenic mimicry formation by the Twist1-Bmi1 connection in hepatocellular carcinoma. Int. J. Mol. Med. 36 (2015), 783–791.
67. Du, W., et al. Is density of neighbourhood restaurants associated with BMI in rural Chinese adults? A longitudinal study from the China Health and Nutrition Survey. BMJ Open, 4, 2014, e004528.
68. Oktyabri, D., et al. EED regulates epithelial-mesenchymal transition of cancer cells induced by TGF-beta. Biochem. Biophys. Res. Commun. 453 (2014), 124–130.
69. Tange, S., et al. JARID2 is involved in transforming growth factor-beta-induced epithelial-mesenchymal transition of lung and colon cancer cell lines. PLoS One, 9, 2014, e115684.
70. Iliopoulos, D., et al. Loss of miR-200 inhibition of Suz12 leads to Polycomb-mediated repression required for the formation and maintenance of cancer stem cells. Mol. Cell 39 (2010), 761–772.
71. Tien, C.L., et al. Snail2/Slug cooperates with Polycomb repressive complex 2 (PRC2) to regulate neural crest development. Development 142 (2015), 722–731.
72. Herranz, N., et al. Polycomb complex 2 is required for E-cadherin repression by the Snail1 transcription factor. Mol. Cell. Biol. 28 (2008), 4772–4781.
73. Tong, Z.T., et al. EZH2 supports nasopharyngeal carcinoma cell aggressiveness by forming a co-repressor complex with HDAC1/HDAC2 and Snail to inhibit E-cadherin. Oncogene 31 (2012), 583–594.
74. Yang, J., et al. Epigenetic silencing of IRF1 dysregulates type III interferon responses to respiratory virus infection in epithelial to mesenchymal transition. Nat. Microbiol., 2, 2017, 17086.
75. Yang, M.H., et al. Bmi1 is essential in Twist1-induced epithelial-mesenchymal transition. Nat. Cell Biol. 12 (2010), 982–992.
76. Chen, J., et al. Snail recruits Ring1B to mediate transcriptional repression and cell migration in pancreatic cancer cells. Cancer Res. 74 (2014), 4353–4363.
77. Song, L.B., et al. The Polycomb group protein Bmi-1 represses the tumor suppressor PTEN and induces epithelial-mesenchymal transition in human nasopharyngeal epithelial cells. J. Clin. Invest. 119 (2009), 3626–3636.
78. Liu, Y., et al. The ZEB1 transcription factor acts in a negative feedback loop with miR200 downstream of Ras and Rb1 to regulate Bmi1 expression. J. Biol. Chem. 289 (2014), 4116–4125.
79. Di Croce, L., Helin, K., Transcriptional regulation by Polycomb group proteins. Nat. Struct. Mol. Biol. 20 (2013), 1147–1155.
80. Esteller, M., Non-coding RNAs in human disease. Nat. Rev. Genet. 12 (2011), 861–874.
81. Yanaka, Y., et al. miR-544a induces epithelial-mesenchymal transition through the activation of WNT signaling pathway in gastric cancer. Carcinogenesis 36 (2015), 1363–1371.
82. Liu, Z., et al. MicroRNA-21 regulates biological behavior by inducing EMT in human cholangiocarcinoma. Int. J. Clin. Exp. Pathol. 8 (2015), 4684–4694.
83. Diaz-Martin, J., et al. A core microRNA signature associated with inducers of the epithelial-to-mesenchymal transition. J. Pathol. 232 (2014), 319–329.
84. Park, S.M., et al. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev. 22 (2008), 894–907.
85. Siemens, H., et al. miR-34 and SNAIL form a double-negative feedback loop to regulate epithelial-mesenchymal transitions. Cell Cycle 10 (2011), 4256–4271.
86. Li, T., et al. Upregulation of long noncoding RNA ZEB1-AS1 promotes tumor metastasis and predicts poor prognosis in hepatocellular carcinoma. Oncogene 35 (2016), 1575–1584.
87. Beltran, M., et al. A natural antisense transcript regulates Zeb2/Sip1 gene expression during Snail1-induced epithelial-mesenchymal transition. Genes Dev. 22 (2008), 756–769.
88. Koirala, P., et al. Long non-coding RNAs as key regulators of cancer metastasis. J. Cancer Metastasis Treat. 2 (2016), 1–10.
89. Battistelli, C., et al. The Snail repressor recruits EZH2 to specific genomic sites through the enrollment of the lncRNA HOTAIR in epithelial-to-mesenchymal transition. Oncogene 36 (2016), 942–955.
90. Liu, Y.W., et al. LincHOTAIR epigenetically silences miR34a by binding to PRC2 to promote the epithelial-to-mesenchymal transition in human gastric cancer. Cell Death Dis., 6, 2015, e1802.
91. Terashima, M., et al. MEG3 long noncoding RNA contributes to the epigenetic regulation of epithelial-mesenchymal transition in lung cancer cell lines. J. Biol. Chem. 292 (2017), 82–99.
92. Thomson, D.W., Dinger, M.E., Endogenous microRNA sponges: evidence and controversy. Nat. Rev. Genet. 17 (2016), 272–283.
93. Xu, Q., et al. Long non-coding RNA regulation of epithelial-mesenchymal transition in cancer metastasis. Cell Death Dis., 7, 2016, e2254.
94. Marcucci, F., et al. Epithelial-mesenchymal transition: a new target in anticancer drug discovery. Nat. Rev. Drug Discov. 15 (2016), 311–325.
95. Chua, K.N., et al. A cell-based small molecule screening method for identifying inhibitors of epithelial-mesenchymal transition in carcinoma. PLoS One, 7, 2012, e33183.
96. Chua, K.N., et al. Combinatorial treatment using targeted MEK and SRC inhibitors synergistically abrogates tumor cell growth and induces mesenchymal-epithelial transition in non-small-cell lung carcinoma. Oncotarget 6 (2015), 29991–30005.
97. Rumman, M., et al. HS-173, a novel PI3K inhibitor suppresses EMT and metastasis in pancreatic cancer. Oncotarget 7 (2016), 78029–78047.
98. Herbertz, S., et al. Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway. Drug Des. Dev. Ther. 9 (2015), 4479–4499.
99. Bhola, N.E., et al. TGF-beta inhibition enhances chemotherapy action against triple-negative breast cancer. J. Clin. Invest. 123 (2013), 1348–1358.
100. Juttermann, R., et al. Toxicity of 5-aza-2′-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation. Proc. Natl. Acad. Sci. U. S. A. 91 (1994), 11797–11801.
101. Bender, C.M., et al. Inhibition of DNA methylation by 5-aza-2′-deoxycytidine suppresses the growth of human tumor cell lines. Cancer Res. 58 (1998), 95–101.
102. Kurkjian, C., et al. DNA methylation: its role in cancer development and therapy. Curr. Probl. Cancer 32 (2008), 187–235.
103. Eades, G., et al. miR-200a regulates SIRT1 expression and epithelial to mesenchymal transition (EMT)-like transformation in mammary epithelial cells. J. Biol. Chem. 286 (2011), 25992–26002.
104. Bi, C., et al. Genome-wide pharmacologic unmasking identifies tumor suppressive microRNAs in multiple myeloma. Oncotarget 6 (2015), 26508–26518.
105. Cicchini, C., et al. Epigenetic control of EMT/MET dynamics: HNF4alpha impacts DNMT3s through miRs-29. Biochim. Biophys. Acta 1849 (2015), 919–929.
106. Lee, E., et al. DNMT1 regulates epithelial-mesenchymal transition and cancer stem cells, which promotes prostate cancer metastasis. Neoplasia 18 (2016), 553–566.
107. Sakamoto, T., et al. A histone deacetylase inhibitor suppresses epithelial-mesenchymal transition and attenuates chemoresistance in biliary tract cancer. PLoS One, 11, 2016, e0145985.
108. Tang, H.M., et al. An epithelial marker promoter induction screen identifies histone deacetylase inhibitors to restore epithelial differentiation and abolishes anchorage independence growth in cancers. Cell Death Discov., 2, 2016, 16041.
109. Ji, M., et al. HDAC inhibitors induce epithelial-mesenchymal transition in colon carcinoma cells. Oncol. Rep. 33 (2015), 2299–2308.
110. Kong, D., et al. Histone deacetylase inhibitors induce epithelial-to-mesenchymal transition in prostate cancer cells. PLoS One, 7, 2012, e45045.
111. Falkenberg, K.J., Johnstone, R.W., Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Nat. Rev. Drug Discov. 13 (2014), 673–691.
112. Shan, B., et al. Requirement of HDAC6 for transforming growth factor-beta1-induced epithelial-mesenchymal transition. J. Biol. Chem. 283 (2008), 21065–21073.
113. Deskin, B., et al. Requirement of HDAC6 for activation of Notch1 by TGF-beta1. Sci. Rep., 6, 2016, 31086.
114. Mobley, R.J., et al. MAP3K4 controls the chromatin modifier HDAC6 during trophoblast stem cell epithelial-to-mesenchymal transition. Cell Rep. 18 (2017), 2387–2400.
115. Meidhof, S., et al. ZEB1-associated drug resistance in cancer cells is reversed by the class I HDAC inhibitor mocetinostat. EMBO Mol. Med 7 (2015), 831–847.
116. Wang, J., et al. Novel histone demethylase LSD1 inhibitors selectively target cancer cells with pluripotent stem cell properties. Cancer Res. 71 (2011), 7238–7249.
117. Mohammad, H.P., et al. A DNA hypomethylation signature predicts antitumor activity of LSD1 inhibitors in SCLC. Cancer Cell 28 (2015), 57–69.
118. Song, X., et al. Corrigendum: Selective inhibition of EZH2 by ZLD1039 blocks H3K27 methylation and leads to potent anti-tumor activity in breast cancer. Sci. Rep., 6, 2016, 24893.
119. Berman, M., et al. Reversing epigenetic mechanisms of drug resistance in solid tumors using targeted microRNA delivery. Expert Opin. Drug Deliv. 13 (2016), 987–998.
120. Lai, A.Y., Wade, P.A., Cancer biology and NuRD: a multifaceted chromatin remodelling complex. Nat. Rev. Cancer 11 (2011), 588–596.
121. Wang, Y., et al. LSD1 is a subunit of the NuRD complex and targets the metastasis programs in breast cancer. Cell 138 (2009), 660–672.
122. Kaur, E., et al. Clinical implications of MTA proteins in human cancer. Cancer Metastasis Rev. 33 (2014), 1017–1024.
123. Boyer, L.A., et al. Polycomb complexes repress developmental regulators in murine embryonic stem cells. Nature 441 (2006), 349–353.
124. Lee, T.I., et al. Control of developmental regulators by Polycomb in human embryonic stem cells. Cell 125 (2006), 301–313.
125. Ezhkova, E., et al. Ezh2 orchestrates gene expression for the stepwise differentiation of tissue-specific stem cells. Cell 136 (2009), 1122–1135.
126. Perdigoto, C.N., et al. Polycomb-mediated repression and Sonic hedgehog signaling interact to regulate Merkel cell specification during skin development. PLoS Genet., 12, 2016, e1006151.
127. Koppens, M.A., et al. Deletion of Polycomb repressive complex 2 from mouse intestine causes loss of stem cells. Gastroenterology 151 (2016), 684–697 e12.
128. Chiacchiera, F., et al. PRC2 preserves intestinal progenitors and restricts secretory lineage commitment. EMBO J. 35 (2016), 2301–2314.
129. Shen, X., et al. EZH1 mediates methylation on histone H3 lysine 27 and complements EZH2 in maintaining stem cell identity and executing pluripotency. Mol. Cell 32 (2008), 491–502.
130. Pasini, D., et al. The Polycomb group protein Suz12 is required for embryonic stem cell differentiation. Mol. Cell. Biol. 27 (2007), 3769–3779.
131. Pasini, D., et al. Suz12 is essential for mouse development and for EZH2 histone methyltransferase activity. EMBO J. 23 (2004), 4061–4071.
132. Xia, R., et al. SUZ12 promotes gastric cancer cell proliferation and metastasis by regulating KLF2 and E-cadherin. Tumour Biol. 36 (2015), 5341–5351.
133. Malouf, G.G., et al. Architecture of epigenetic reprogramming following Twist1-mediated epithelial-mesenchymal transition. Genome Biol., 14, 2013, R144.
134. Yu, H., et al. PRC2/EED-EZH2 complex is up-regulated in breast cancer lymph node metastasis compared to primary tumor and correlates with tumor proliferation in situ. PLoS One, 7, 2012, e51239.
135. Kim, H., et al. AEBP2 as a potential targeting protein for Polycomb repression complex PRC2. Nucleic Acids Res. 37 (2009), 2940–2950.
136. Nekrasov, M., et al. Pcl-PRC2 is needed to generate high levels of H3-K27 trimethylation at Polycomb target genes. EMBO J. 26 (2007), 4078–4088.
137. Pasini, D., et al. JARID2 regulates binding of the Polycomb repressive complex 2 to target genes in ES cells. Nature 464 (2010), 306–310.
138. Wiegand, K.C., et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. N. Engl. J. Med. 363 (2010), 1532–1543.
139. Versteege, I., et al. Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer. Nature 394 (1998), 203–206.
140. Li, M., et al. Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma. Nat. Genet. 43 (2011), 828–829.
141. Shain, A.H., Pollack, J.R., The spectrum of SWI/SNF mutations, ubiquitous in human cancers. PLoS One, 8, 2013, e55119.
142. Varela, I., et al. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature 469 (2011), 539–542.
143. Ramadoss, S., et al. Histone demethylase KDM6B promotes epithelial-mesenchymal transition. J. Biol. Chem. 287 (2012), 44508–44517.
144. Pereira, F., et al. KDM6B/JMJD3 histone demethylase is induced by vitamin D and modulates its effects in colon cancer cells. Hum. Mol. Genet. 20 (2011), 4655–4665.
145. Ezponda, T., et al. The histone methyltransferase MMSET/WHSC1 activates TWIST1 to promote an epithelial-mesenchymal transition and invasive properties of prostate cancer. Oncogene 32 (2013), 2882–2890.
146. Cho, M.H., et al. DOT1L cooperates with the c-Myc-p300 complex to epigenetically derepress CDH1 transcription factors in breast cancer progression. Nat. Commun., 6, 2015, 7821.
147. Cardenas, H., et al. EZH2 inhibition promotes epithelial-to-mesenchymal transition in ovarian cancer cells. Oncotarget 7 (2016), 84453–84467.
148. Zhou, D., et al. RBP2 induces stem-like cancer cells by promoting EMT and is a prognostic marker for renal cell carcinoma. Exp. Mol. Med., 48, 2016, e238.
149. Wang, S., et al. RBP2 induces epithelial-mesenchymal transition in non-small cell lung cancer. PLoS One, 8, 2013, e84735.
150. Enkhbaatar, Z., et al. KDM5B histone demethylase controls epithelial-mesenchymal transition of cancer cells by regulating the expression of the microRNA-200 family. Cell Cycle 12 (2013), 2100–2112.
151. Shao, P., et al. Histone demethylase PHF8 promotes epithelial to mesenchymal transition and breast tumorigenesis. Nucleic Acids Res. 45 (2017), 1687–1702.
152. Li, S., et al. KDM4B promotes epithelial-mesenchymal transition through up-regulation of ZEB1 in pancreatic cancer. Acta Biochim. Biophys. Sin. (Shanghai) 47 (2015), 997–1004.
153. Kim, J.H., et al. UTX and MLL4 coordinately regulate transcriptional programs for cell proliferation and invasiveness in breast cancer cells. Cancer Res. 74 (2014), 1705–1717.
154. Choi, H.J., et al. UTX inhibits EMT-induced breast CSC properties by epigenetic repression of EMT genes in cooperation with LSD1 and HDAC1. EMBO Rep. 16 (2015), 1288–1298.
155. Gao, Y., et al. The dual function of PRMT1 in modulating epithelial-mesenchymal transition and cellular senescence in breast cancer cells through regulation of ZEB1. Sci. Rep., 6, 2016, 19874.
156. Strobl-Mazzulla, P.H., et al. Histone demethylase JmjD2A regulates neural crest specification. Dev. Cell 19 (2010), 460–468.
157. Byles, V., et al. SIRT1 induces EMT by cooperating with EMT transcription factors and enhances prostate cancer cell migration and metastasis. Oncogene 31 (2012), 4619–4629.
158. Liang, Y., et al. Epigenetic Activation of TWIST1 by MTDH Promotes Cancer Stem-like Cell Traits in Breast Cancer. Cancer Res. 75 (2015), 3672–3680.
159. Kaimori, A., et al. Histone deacetylase inhibition suppresses the transforming growth factor beta1-induced epithelial-to-mesenchymal transition in hepatocytes. Hepatology 52 (2010), 1033–1045.
160. Park, I.H., et al. Trichostatin A Inhibits Epithelial Mesenchymal Transition Induced by TGF-beta1 in Airway Epithelium. PLoS One, 11, 2016, e0162058.
161. Lin, T., et al. Requirement of the histone demethylase LSD1 in Snai1-mediated transcriptional repression during epithelial-mesenchymal transition. Oncogene 29 (2010), 4896–4904.
162. Dong, C., et al. G9a interacts with Snail and is critical for Snail-mediated E-cadherin repression in human breast cancer. J. Clin. Invest 122 (2012), 1469–1486.
163. Yang, F., et al. SET8 promotes epithelial-mesenchymal transition and confers TWIST dual transcriptional activities. EMBO J. 31 (2012), 110–123.
164. Hou, L., et al. SET8 induces epithelialmesenchymal transition and enhances prostate cancer cell metastasis by cooperating with ZEB1. Mol. Med. Rep. 13 (2016), 1681–1688.
165. Cakouros, D., et al. Twist-1 induces Ezh2 recruitment regulating histone methylation along the Ink4A/Arf locus in mesenchymal stem cells. Mol. Cell. Biol. 32 (2012), 1433–1441.
166. Liu, S., et al. G9a is essential for EMT-mediated metastasis and maintenance of cancer stem cell-like characters in head and neck squamous cell carcinoma. Oncotarget 6 (2015), 6887–6901.
167. Dong, C., et al. Interaction with Suv39H1 is critical for Snail-mediated E-cadherin repression in breast cancer. Oncogene 32 (2013), 1351–1362.
168. Shi, Y., et al. Coordinated histone modifications mediated by a CtBP co-repressor complex. Nature 422 (2003), 735–738.
169. Hou, Z., et al. The LIM protein AJUBA recruits protein arginine methyltransferase 5 to mediate SNAIL-dependent transcriptional repression. Mol. Cell. Biol. 28 (2008), 3198–3207.
170. Sun, L., et al. MPP8 and SIRT1 crosstalk in E-cadherin gene silencing and epithelial-mesenchymal transition. EMBO Rep. 16 (2015), 689–699.
171. Strobl-Mazzulla, P.H., Bronner, M.E., A PHD12-Snail2 repressive complex epigenetically mediates neural crest epithelial-to-mesenchymal transition. J. Cell Biol. 198 (2012), 999–1010.
172. Tripathi, M.K., et al. Regulation of BRCA2 gene expression by the SLUG repressor protein in human breast cells. J. Biol. Chem. 280 (2005), 17163–17171.
173. Aghdassi, A., et al. Recruitment of histone deacetylases HDAC1 and HDAC2 by the transcriptional repressor ZEB1 downregulates E-cadherin expression in pancreatic cancer. Gut 61 (2012), 439–448.